Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Lyra Therapeutics Provides Corporate Update

WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”) today announced that its Board of Directors has decided to suspend further development of LYR-210, the Company's lead product candidate for the treatment of chronic rhinosinusitis (CRS).

Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

– Company plans new, confirmatory Phase 3 clinical trial of LYR-210 for treatment of chronic rhinosinusitis (CRS) without nasal polyps, on path to NDA submission –